MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617065713 A) filed by Bayer Aktiengesellschaft; and Bayer As on May 25, 2026, for Radiopharmaceutical Complexes And Combinations.
Inventors include Oden, Felix; Zitzmann-Kolbe, Sabine; Trautwein, Mark; Politz, Oliver; Hagemann, Urs Beat; Siegel, Franziska; Tomszak, Florian; Schatz, Christoph; Berg-Larsen, Axel; Moen, Ingrid; Feng, Yuan Zeng; Cruciani, Vronique; Cuthbertson, Alan; Biseth, Katrine Wickstroem; and Mobergslien, Anne.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention relates to tissue-targeting compounds. In particular, the present invention relates to tissue-targeting compounds comprising a monoclonal antibody or an antigen-binding fragment thereof having binding affinity for HER2, GPC3, CEACAM5, TROP2, GUCY2C, cMet, FolRa, DLL3, Nectin-4 or STEAP1. Further, the present invention relates to combinations, preferably pharmaceutical combinations comprising a tissue-targeting compound of formula (I) and a further pharmaceutical agent. Said combinations are useful in therapy, preferably in treating hyperproliferative diseases such as cancer.
Disclaimer: Curated by HT Syndication.
